Curaleaf (OTCMKTS:CURLF) Upgraded by Zacks Research to “Strong-Buy” Rating

Curaleaf (OTCMKTS:CURLF) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

Curaleaf Price Performance

CURLF stock opened at $9.75 on Tuesday. Curaleaf has a 12 month low of $2.83 and a 12 month high of $15.15. The company has a current ratio of 1.56, a quick ratio of 0.74 and a debt-to-equity ratio of 1.05. The company has a 50-day moving average price of $7.56 and a 200 day moving average price of $7.56. The stock has a market cap of $2.28 billion, a PE ratio of -25.00 and a beta of 1.51.

Curaleaf (OTCMKTS:CURLF) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.51. The company had revenue of $324.23 million for the quarter, compared to analyst estimates of $316.62 million. Curaleaf had a negative net margin of 7.76% and a negative return on equity of 8.11%. Equities research analysts anticipate that Curaleaf will post -0.31 earnings per share for the current year.

About Curaleaf

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.